Please assess the completion status of the following clinical trial:

Trial Title: A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with breast cancer, at a disseminated stage~* patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed~* alive patients authorizing the extraction and analysis of their biological samples.~Exclusion Criteria:~* patients with a second neoplasia~* deceased patients~* patients who have not agreed to participate in the study~* HER2 positive patients~* patients with CNS metastases when first treated with bevacizumab in combination with paclitaxel~* patients with local-regional recurrence only and~* patients with status NED (resected metastases)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).